Regression of Liver Fibrosis
- PMID: 28201843
- DOI: 10.1055/s-0036-1597816
Regression of Liver Fibrosis
Abstract
Liver fibrosis is the final common pathway of chronic or iterative liver damage. Advanced chronic fibrosis is described as cirrhosis with a loss of architecture and attendant functional failure and the development of life-threatening complications. However, compelling evidence from rodent models and human studies indicates that if the injury is removed liver fibrosis is reversible. Hepatocytes, activated hepatic stellate cells, endothelial and immune cells, particularly macrophages, cooperate in the establishment and resolution of liver fibrosis. Here the authors provide a short overview of the mechanisms regulating the profibrotic and proresolution response, with the aim of highlighting potential new therapeutic targets. Liver disease is a major unmet medical need; currently, the sole approaches are the withdrawal of the injurious stimulus and liver transplantation. The authors conclude with a brief review of the feasibility of macrophage-based cell therapy for liver fibrosis.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Similar articles
-
In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis.World J Gastroenterol. 2017 Dec 14;23(46):8152-8168. doi: 10.3748/wjg.v23.i46.8152. World J Gastroenterol. 2017. PMID: 29290652 Free PMC article.
-
Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166. doi: 10.1038/s41575-020-00372-7. Epub 2020 Oct 30. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33128017 Review.
-
Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:99-104. doi: 10.1111/jgh.12017. J Gastroenterol Hepatol. 2013. PMID: 23855303 Review.
-
New insights into therapeutic strategies for targeting hepatic macrophages to alleviate liver fibrosis.Int Immunopharmacol. 2025 Jun 17;158:114864. doi: 10.1016/j.intimp.2025.114864. Epub 2025 May 15. Int Immunopharmacol. 2025. PMID: 40378438 Review.
-
Monocytes and macrophages as cellular targets in liver fibrosis.Inflamm Allergy Drug Targets. 2009 Sep;8(4):307-18. doi: 10.2174/187152809789352230. Inflamm Allergy Drug Targets. 2009. PMID: 19534673 Review.
Cited by
-
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review.Front Pharmacol. 2020 Sep 4;11:568032. doi: 10.3389/fphar.2020.568032. eCollection 2020. Front Pharmacol. 2020. PMID: 33013406 Free PMC article. Review.
-
Vanin 1: Its Physiological Function and Role in Diseases.Int J Mol Sci. 2019 Aug 9;20(16):3891. doi: 10.3390/ijms20163891. Int J Mol Sci. 2019. PMID: 31404995 Free PMC article. Review.
-
HBO1 as an Important Target for the Treatment of CCL4-Induced Liver Fibrosis and Aged-Related Liver Aging and Fibrosis.Oxid Med Cell Longev. 2022 Dec 6;2022:1881519. doi: 10.1155/2022/1881519. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36524217 Free PMC article.
-
The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles.RSC Adv. 2018 Feb 12;8(12):6699-6708. doi: 10.1039/c7ra10847h. eCollection 2018 Feb 6. RSC Adv. 2018. PMID: 35540380 Free PMC article.
-
Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats.Front Pharmacol. 2018 Jul 13;9:709. doi: 10.3389/fphar.2018.00709. eCollection 2018. Front Pharmacol. 2018. PMID: 30057547 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical